The scientific backdrop is striking. Years before pivotal trial data existed, researchers including Ronald Grunstein and colleagues argued in the journal Sleep that incretin-based pharmacotherapy could positively disrupt the management of obesity-related sleep apnea, challenging the field’s heavy reliance on mechanical therapies and its limited engagement with weight management as a principal therapeutic strategy. That prediction has now matured into clinical reality. Tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, produces substantial weight reduction, and the SURMOUNT-OSA program demonstrated meaningful reductions in sleep-disordered breathing measures among participants with obesity. Secondary analyses published in Nature Medicine have extended the picture, linking tirzepatide to improvements in obstructive sleep apnea-related cardiometabolic risk markers. For a disorder in which excess adipose tissue drives airway collapse through anatomical loading, reduced lung volumes, and inflammatory and ventilatory effects, a drug that targets the underlying biology is not simply an adjunct. It is, for some patients, a disease-modifying therapy.

Yet the editorial’s central argument is not a celebration of pharmacology. It is a careful examination of professional boundaries. Sleep medicine specialists, the authors acknowledge, may feel conflicted about prescribing obesity-directed pharmacotherapy to improve sleep apnea. The sources of that conflict are concrete: uncertainty about scope of practice, weight stigma, operational burden, access and cost concerns, and limited training in weight management. For many sleep clinicians, the new era requires a shift from counseling patients about weight and referring medication management elsewhere, toward deciding which parts of weight management now belong within sleep medicine itself. Prescribing medication, the authors note, is generally within the legal reach of physicians, which makes this boundary more difficult to draw than those involving oral appliance fabrication or upper-airway surgery, where specialized technical skills clearly separate the fields.

To frame the problem, the editorial offers a geometric metaphor that is likely to circulate widely in sleep medicine education. Picture two overlapping circles. One circle is sleep medicine: diagnosis of sleep apnea, physiologic phenotyping, symptom assessment, positive airway pressure therapy, oral appliance therapy, surgical referral, adherence support, and objective reassessment of sleep-disordered breathing. The second circle is obesity medicine and metabolic care: obesity diagnosis and staging, pharmacotherapy, nutrition, physical activity, behavioral support, medication safety, cardiometabolic risk management, bariatric surgery referral, and weight maintenance. The overlap between the two circles is what the authors call obesity-informed sleep apnea care, and it is in this intersection that the future of the specialty is being negotiated.

Crucially, the authors insist that this overlap does not require every sleep physician to become an obesity medicine specialist. What it does require is enough competence, structure, and humility to guide patients through a therapy that now directly touches the sleep disorder being treated. In the overlap zone, sleep clinicians identify patients with sleep apnea and obesity who may benefit from weight-based therapy, counsel without stigma, explain that weight loss may improve but not necessarily eliminate sleep apnea, integrate pharmacologic weight-loss therapy with positive airway pressure and other established treatments, monitor sleep-specific outcomes, and determine when repeat sleep testing is needed. The editorial is equally clear about what should not happen. Abdication, treating obesity pharmacotherapy as someone else’s concern even when it alters apnea severity, symptoms, hypoxic burden, and follow-up testing, serves no one. Neither does overreach, the assumption that every sleep physician must deliver comprehensive obesity care.

The distinction between the overlap zone and comprehensive obesity medicine is drawn with technical precision. Full obesity medicine encompasses complete obesity staging, long-term pharmacologic management across multiple indications, complex adverse-effect monitoring, nutritional assessment, medication interactions, eating disorder concerns, pregnancy considerations, bariatric surgery selection, weight-regain management, stigma management, and longitudinal cardiometabolic care. Some sleep physicians may pursue this deeper expertise, including formal certification through the American Board of Obesity Medicine, a pathway the authors encourage. But they argue that such certification should not define the minimum identity of a sleep specialist. The analogy they invoke is restless legs syndrome, a condition in which sleep clinicians routinely evaluate iron status and prescribe iron therapy while recognizing that complex anemia, malabsorption, pregnancy, or kidney disease may require broader medical evaluation. The boundary, they write, is neither abandonment nor annexation. It is competent ownership of the sleep-relevant problem, with collaboration when the underlying condition exceeds sleep-specific expertise.

From this conceptual framework, the editorial derives a practical implementation model with three layers. The first is universal sleep medicine competency: every sleep physician should understand obesity as a chronic, biologically mediated disease rather than a failure of willpower, know the sleep apnea-relevant evidence for incretin-based therapies, counsel respectfully, recognize when medication may enter the treatment conversation, and know when to refer. The second is structured co-management, in which sleep centers build explicit pathways with primary care, endocrinology, obesity medicine, clinical pharmacy, nutrition, behavioral health, and bariatric surgery. The third is advanced sleep-obesity practice, in which some programs pursue deeper expertise through obesity medicine certification or establish embedded metabolic sleep clinics. This tiered architecture acknowledges the variable readiness of practices, from referral-only models to fully integrated metabolic sleep programs, and it converts a broad clinical question into an actionable agenda.

The institutional machinery behind this shift is already in motion. The American Academy of Sleep Medicine convened an Obesity Management Task Force in 2025 to discover emerging best practices, develop practical member resources, and propose a longer-term strategy. The task force curated physician- and patient-facing resources, modeled obesity management approaches across different practice settings, and surveyed Academy members about readiness, barriers, and implementation needs. In March 2026, the AASM Obesity Management Strategy Summit brought together task force members, Academy leadership and staff, and invited stakeholders from obesity medicine, bariatric surgery, endocrinology, nutrition, and patient advocacy. Through foundational presentations, small-group discussions, multivoting, and effort-impact prioritization, participants identified gaps and staged potential responses. The resulting summit summary, the editorial argues, is more than a meeting report; it is a field map showing where consensus is emerging, where evidence remains incomplete, and where implementation will demand shared work across clinical guidance, education, referral pathways, insurance coverage, stigma reduction, patient engagement, and workforce development.

The educational implications reach into the structure of training itself. The authors call for fellowship curricula that address the bidirectionality of obesity and sleep apnea, weight management pharmacotherapy, respectful communication, medication safety, outcome monitoring, and collaborative care models. Continuing education should help practicing clinicians understand indications, risks, monitoring requirements, and referral thresholds. Future clinical guidelines, they argue, must specify how pharmacologic weight management integrates with positive airway pressure, oral appliances, surgery, positional therapy, and follow-up testing. Accredited sleep centers, they suggest, may eventually need to demonstrate not that they prescribe obesity medications, but that they maintain a coherent pathway for patients who have both sleep apnea and obesity. The textbook of five years from now, the editorial predicts, should contain a serious section on metabolic sleep medicine covering obesity physiology, incretin-based therapies, bariatric surgery outcomes, indications and contraindications for medical or surgical obesity treatment, repeat testing after weight loss, residual sleep apnea, equity of access, stigma, and adherence, without becoming a bariatric medicine textbook in its own right.

The deeper significance of this editorial lies in how it reframes a therapeutic disruption as an exercise in professional self-definition. Grunstein and colleagues originally asked whether incretin-based pharmacotherapy would be a revolution or a pipe dream. The answer, the authors conclude, is neither fantasy nor simple replacement of existing therapies. It is a disruption that demands clinical architecture: clear decisions about which parts of obesity management are necessary for excellent sleep apnea care, which require structured collaboration, and which belong primarily to comprehensive obesity medicine. If sleep medicine answers that question with discipline, humility, and vision, the field can expand its therapeutic reach without losing its center of gravity, and millions of patients whose breathing pauses at night are driven by biology that a prescription can now address may finally receive care designed for the whole of their disease.

Subject of Research: Integration of obesity pharmacotherapy into obstructive sleep apnea care

Article Title: Obesity-informed OSA care: defining the expanding boundary of sleep medicine

Article References: Morgenthaler, T. I., Sepulveda, R., Bandyopadhyay, A., Hawa, R., Khan, S. S., Nowalk, N. C., Stager, L., Tadros, M., Tu, X., Vieira, N. M., & Wojeck, B. (2026). Obesity-informed OSA care: defining the expanding boundary of sleep medicine. Journal of Clinical Sleep Medicine, 22(1), Article 144. https://doi.org/10.1007/s44470-026-00157-w

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00157-w

Keywords: obstructive sleep apnea, obesity medicine, tirzepatide, incretin therapies, sleep medicine, SURMOUNT-OSA, weight management, AASM, positive airway pressure, metabolic sleep medicine, clinical guidelines, medical education

The mechanistic foundations of the three drugs explain much of their divergent behaviour. Semaglutide is a human GLP-1 analog with 94 percent sequence identity to the native hormone, engineered with an Aib substitution at position 8 to resist degradation by the enzyme DPP-4 and a C18 fatty diacid side chain at position 26 that binds albumin and extends its half-life to roughly seven days. Liraglutide, with 97 percent homology, carries a shorter C16 palmitic acid chain that yields a half-life of about 13 hours, confining it to once-daily injection. Tirzepatide, a 39-amino-acid synthetic ‘twincretin’, activates both the GIP and GLP-1 receptors and carries a C20 fatty diacid moiety that prolongs systemic exposure to approximately five days. These structural choices dictate dosing convenience, adherence and, ultimately, how patients experience therapy.

Formulation differences add a practical dimension to drug selection. Semaglutide is the only agent in the class available as an oral tablet, made possible by the absorption enhancer SNAC, though oral bioavailability is only about one percent and the tablet must be taken fasting with water only. Subcutaneous semaglutide achieves roughly 89 percent bioavailability. Liraglutide requires daily subcutaneous injection, which may deter some patients, while tirzepatide is delivered exclusively as a once-weekly autoinjector. Real-world data show semaglutide achieves approximately 40 percent treatment persistence at one year, higher than liraglutide, and tirzepatide’s weekly dosing is expected to support strong adherence, though long-term real-world outcomes remain pending. Notably, liraglutide is the only one of the three approved for adolescents with both type 2 diabetes and obesity.

On glycaemic control, the review’s synthesis of trial data reveals a clear hierarchy. Subcutaneous semaglutide at 0.5 to 1.0 mg reduced HbA1c by 1.3 to 1.8 percent across the SUSTAIN program, outperforming placebo, sitagliptin, exenatide and basal insulin, while oral semaglutide achieved reductions of 1.3 to 2.0 percent in the PIONEER trials, edging out subcutaneous liraglutide 1.8 mg in PIONEER 4. Liraglutide, tested in the LEAD program at 1.2 and 1.8 mg, produced HbA1c reductions of 0.7 to 1.5 percent. Tirzepatide, however, set a new benchmark: in SURPASS-2, doses of 5, 10 and 15 mg lowered HbA1c by approximately 2.01, 2.24 and 2.30 percent respectively, surpassing semaglutide 1 mg, which achieved 1.86 percent. Pooled analyses indicate more than 90 percent of tirzepatide recipients reached the HbA1c target below 7.0 percent.

Weight outcomes follow a similar pattern. Semaglutide 2.4 mg weekly produced mean weight losses of up to 14.9 percent at 68 weeks in the STEP program and 10.2 percent over four years in the SELECT trial, accompanied by a 7.7 cm reduction in waist circumference. Liraglutide at 3.0 mg daily achieved approximately 4.91 kg of weight loss in meta-analysis, with BMI declines and waist reductions around 3.55 cm. Tirzepatide again led the field: SURPASS trials recorded weight reductions ranging from 5.3 to 17.1 kg depending on dose and comparator, and in the SURMOUNT-4 trial participants with obesity maintained mean reductions of approximately 20.9 percent at 88 weeks. A SURPASS-3 substudy further showed tirzepatide reduced hepatic fat and visceral adipose tissue, with waist circumference falling by up to 18.5 cm at the highest dose.

Lipid modulation, a subtler but clinically relevant domain, also favoured the dual agonist. Semaglutide produced modest reductions of roughly 3 to 6 percent in total cholesterol, 5 to 10 percent in LDL cholesterol and 10 to 15 percent in triglycerides, with slight HDL increases, mechanisms attributed to reduced free fatty acid influx to the liver and enhanced lipoprotein lipase activity. Liraglutide showed mild improvements, particularly in triglycerides and apolipoprotein B, with dose-dependent variability. Tirzepatide delivered the most pronounced effects: meta-analytic estimates showed triglyceride reductions of 13 to 22 percent, total cholesterol reductions of roughly 5 to 7 percent, and HDL increases of 4 to 7 percent, alongside reductions in large triglyceride-rich lipoproteins and small LDL particles. The authors caution, however, that these are surrogate markers whose translation into fewer cardiovascular events remains unproven.

Where hard clinical outcomes exist, the picture becomes more differentiated. In the SUSTAIN-6 cardiovascular outcomes trial, semaglutide reduced three-point major adverse cardiovascular events—cardiovascular death, nonfatal myocardial infarction and nonfatal stroke—by 26 percent, with post hoc analyses suggesting a roughly 35 percent reduction in stroke incidence, the strongest cerebrovascular signal in the class. Liraglutide, in the landmark LEADER trial, achieved a 13 percent MACE reduction driven primarily by significant reductions in cardiovascular death, making it particularly relevant for patients whose dominant risk is mortality. Tirzepatide has not yet completed a dedicated outcomes trial, but a pre-specified meta-analysis of pooled SURPASS data, including the high-risk SURPASS-4 cohort, reported a 27 percent relative risk reduction in three-point MACE and a 46 percent reduction in four-point MACE—promising signals awaiting confirmation from the ongoing SURPASS-CVOT.

Kidney outcomes reveal mechanistic distinctions with direct clinical implications. Semaglutide cut the risk of new or worsening nephropathy by 36 percent in SUSTAIN-6, slowed eGFR decline in pooled analyses, and extended renal protection to non-diabetic individuals with cardiovascular disease in the SELECT trial, suggesting partially glucose-independent benefit. Liraglutide reduced nephropathy risk by 22 percent in LEADER, but its effect appears largely mediated by improved glycaemic control and blood pressure rather than direct nephroprotection. Tirzepatide, studied in SURPASS-4’s chronic kidney disease cohort, attenuated eGFR decline and reduced macroalbuminuria across all doses, and causal mediation analysis indicated that only 40 to 60 percent of the renal benefit was explained by traditional factors such as HbA1c, blood pressure and weight—implying a substantial glucose-independent component that may make it especially valuable for patients with diabetic kidney disease.

Safety profiles across the class are broadly favourable, dominated by gastrointestinal effects. Nausea, vomiting and diarrhoea are common with all three agents, typically arising during dose escalation and subsiding within four to eight weeks with gradual titration. Tirzepatide produces the highest frequency and severity of gastrointestinal events, including constipation, likely reflecting its GIP receptor activity, followed by semaglutide and then liraglutide, which tends to cause milder, more gradual symptoms. Gallbladder events such as cholelithiasis have been observed with all agents, largely associated with rapid weight loss, and pancreatitis is rare. Hypoglycaemia is uncommon unless the drugs are combined with insulin or sulfonylureas. All three are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. In renal impairment, tirzepatide maintains stable pharmacokinetics even in dialysis patients, an advantage over semaglutide and liraglutide, which require caution in end-stage renal disease.

The review’s overarching conclusion is a call for calibrated clinical judgement rather than a declaration of winners. Tirzepatide demonstrably offers the greatest HbA1c and weight reductions, semaglutide combines substantial efficacy with formulation flexibility and the best stroke evidence, and liraglutide provides a proven mortality benefit with the broadest paediatric indication. Yet because every comparison in the analysis is indirect—drawn from separate trials with different populations, comparators and endpoints—the authors insist the findings should be treated as hypothesis-generating, not definitive proof of superiority. They identify direct head-to-head trials, particularly tirzepatide versus higher-dose semaglutide, long-term cardiovascular and renal outcome data for tirzepatide, and evidence in underrepresented populations as critical gaps. Until those trials report, treatment decisions must remain individualized, weighing comorbidities, renal function, tolerability, dosing preferences and each patient’s therapeutic priorities.

Subject of Research: Comparative cardiometabolic effects of the incretin-based therapies semaglutide, liraglutide and tirzepatide in type 2 diabetes and obesity

Article Title: Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review

Article References: Bawadi, H., Abuhijleh, H., Nofal, M., Zakaria, Z. Z., & Al‐Asmakh, M. (2026). Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review. Endocrinology, Diabetes & Metabolism, 9(5), Article e70338. https://doi.org/10.1002/edm2.70338

Image Credits: AI Generated

DOI: 10.1002/edm2.70338

Keywords: semaglutide, liraglutide, tirzepatide, GLP-1 receptor agonists, type 2 diabetes, obesity, HbA1c, weight loss, cardiovascular outcomes, renal function, lipid profile, incretin therapies

The study, led by Chia Siang Kow and colleagues, took a fresh statistical look at the six clinical studies and ten intervention arms that tracked semaglutide or tirzepatide after treatment discontinuation, drawing on data covering 1776 participants. Rather than relying on simple pooled averages, the researchers reconstructed the arm-level data and applied a Bayesian hierarchical longitudinal model, a statistical framework that jointly models repeated measurements over time while explicitly accounting for variability between study arms. This approach allowed the team to go beyond asking how many kilograms are regained each month and instead translate the trajectory into clinically meaningful milestones, complete with full probability distributions that quantify uncertainty.

The headline finding is that people who stop taking these medications regain an estimated 1.04 kilograms per month on average, with a 95 percent credible interval of 0.80 to 1.29 kilograms per month. The modelled average participant had lost 15.35 kilograms by the time treatment ended. Under the linear model assumed by the researchers, half of that hard-won loss was projected to return within about 7.5 months, and participants were projected to be back at their baseline weight by roughly 15 months after stopping. In practical terms, the clock on the treatment’s benefits starts ticking almost the moment the final injection wears off.

The month-by-month trajectory is particularly striking. Within the follow-up window actually observed in the trials, which extended to 52 weeks, the modelled average weight change was still below baseline at six months, at minus 9.12 kilograms, but by then approximately 41 percent of the initial weight loss had already been regained. At nine months the average was minus 6.01 kilograms, corresponding to 62 percent regained, and by twelve months the average stood at minus 2.90 kilograms, meaning roughly 83 percent of the lost weight had returned. The posterior probability that the average trajectory had regained at least half of the initial weight loss climbed from just 12.5 percent at six months to 86.7 percent at nine months and a near-certain 99.5 percent at one year.

It is important to understand the mathematical machinery behind these numbers. The researchers assumed a constant linear regain slope rather than a curving trajectory, a choice justified because follow-up data were sparse and a prior systematic review had found that adding a nonlinear term did not improve model fit. Each study arm was treated as a repeated-measures trajectory with its own random effects for both the weight loss present at discontinuation and the subsequent regain rate. The Bayesian estimation relied on full Markov chain Monte Carlo sampling, with convergence confirmed by R-hat statistics hovering at approximately 1.00 and large effective sample sizes for the key slope parameters. Estimates extending beyond the maximum observed follow-up of 52 weeks, including the projected return to baseline at 15 months, are explicitly flagged as extrapolations of the average trajectory rather than directly observed outcomes.

One of the most provocative aspects of the analysis is its comparison of the two drugs. Tirzepatide arms showed a numerically faster unadjusted regain rate of 1.10 kilograms per month compared with 0.89 kilograms per month for semaglutide, and projected return to baseline was correspondingly sooner, at roughly 14.5 months versus 17.3 months. But when the researchers adjusted for the magnitude of initial weight loss and post-discontinuation support in a Bayesian meta-regression, the drug difference essentially vanished. The adjusted effect of tirzepatide versus semaglutide was a negligible minus 0.04 kilograms per month, with a posterior probability of only 40.2 percent that tirzepatide regains faster. In other words, the apparent difference in rebound between the two drugs likely reflects differences in how much weight was lost in the first place, not any inherent difference in the physiology of regain.

That observation points to one of the study’s most interesting exploratory findings: greater initial weight loss was itself the strongest directional predictor of faster absolute regain. Each additional 5 kilograms of weight lost during treatment was associated with a 0.20 kilograms per month faster regain slope, a result carrying a 92.1 percent posterior probability, though the credible interval included zero. The authors caution that this association may partly reflect mathematical coupling, since a larger initial loss simply creates more opportunity for absolute regain. Meanwhile, behavioural or lifestyle support after discontinuation showed a directional association with slower regain, an estimated effect of minus 0.19 kilograms per month with an 87.2 percent probability of benefit, but the imprecise estimate means the finding remains inconclusive. With only ten intervention arms available, all meta-regression results are explicitly exploratory and hypothesis-generating rather than definitive.

Sensitivity analyses reinforced the robustness of the core conclusion. A contrast analysis using the randomised differences between intervention and control arms showed a similar direction of effect, though with less precision. A post hoc analysis excluded the three SURPASS-1 arms, which came from a trial of adults with Type 2 diabetes receiving tirzepatide as glucose-lowering monotherapy rather than for weight management. Excluding those arms left the monthly regain slope essentially unchanged at 0.95 kilograms per month, though the projected time to 50 percent regain lengthened to 9.42 months because the average initial weight loss among the remaining arms was greater. The qualitative message of rapid regain survived every stress test the researchers applied.

The clinical implications are considerable. Because discontinuation is common in routine practice, driven by cost, tolerability problems, access restrictions, treatment fatigue and genuine uncertainty about how long therapy should last, the findings suggest that clinicians should plan proactive monitoring within the first several months after stopping treatment, when early regain can be identified and maintenance strategies reassessed. The authors are careful to note that their data do not determine whether dose tapering, lower-dose maintenance, drug switching, intermittent treatment or any specific behavioural programme can prevent regain; those questions require dedicated trials. They also stress that the analysis captured body-weight trajectories only, so any statements about cardiometabolic benefits, cost-effectiveness or the consequences of fixed-duration treatment policies remain hypotheses informed by the weight pattern rather than direct findings.

What the study ultimately delivers is a statistically rigorous quantification of something patients and clinicians have long suspected: incretin-based anti-obesity medications suppress appetite and enable weight loss while they are active, and withdrawing that physiological support removes the very mechanism holding the weight down. Between-study heterogeneity was real but moderate, with a between-arm standard deviation of 6.78 kilograms for initial weight loss and 0.26 kilograms per month for the regain slope, suggesting that while individual experiences vary, the average trajectory is consistently steep. As these drugs reshape obesity medicine and public expectations, the analysis argues that their long-term value must be judged not only by the dramatic losses achieved during treatment but by an honest accounting of what follows when the treatment ends, and by research that extends follow-up beyond one year, reports regain in both absolute and percentage terms, and directly tests the maintenance strategies that patients will increasingly demand.

Subject of Research: Weight regain after discontinuation of the incretin-based anti-obesity medications semaglutide and tirzepatide

Article Title: Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis

Article References: Kow, C. S., Thiruchelvam, K., Ramachandram, D. S., & Zaihan, A. F. (2026). Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 9(5), Article e70325. https://doi.org/10.1002/edm2.70325

Image Credits: AI Generated

DOI: 10.1002/edm2.70325

Keywords: semaglutide, tirzepatide, weight regain, obesity, incretin therapies, GLP-1 receptor agonists, Bayesian meta-analysis, treatment discontinuation, weight loss maintenance, anti-obesity pharmacotherapy, Weight, Regain